| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
Description: Sinomenine HCl (Cucoline), the hydrochloride salt of Sinomenine, is a naturally occuring alkaloid isolated from the root of the plant Sinomenium acutum. It is a blocker of the NF-κB activation with anticancer and anti-inflammatory effects. Sinomenine also is an activator of μ-opioid receptor. It has been used in traditional medicine in China to treat rheumatic arthritis. Sinomenine has a wide spectrum of analgesic effect in rodent models of nociceptive, inflammatory and neuropathic pain.
| Targets |
|
|
|---|---|---|
| ln Vitro |
Sinomenine downregulates HIAP, Bcl-2, and survivin while activating caspase-3, caspase-8, and caspase-9 in U87 cells to cause apoptotic death. The expression of phosphorylated STAT3 (p-STAT3) is reduced by Sinomenine both in vivo and in vitro. It has protective effects against a variety of cancer types, such as breast cancer cells, esophageal carcinoma cells, hepatocellular carcinoma cells, gastric adenocarcinoma cells, lung cancer cells, and colon carcinoma cells. Treatment with Sinomenine results in a dose- and time-dependent inhibition of growth in U87, with an IC50 of SM ranging from 178 μM to 380 μM. Sinomenine obviously reduces cell viability when applied to U251, U373, Hs683 and T98G for 48 hours; the IC50 values are 342.7 μM, 430.2 μM, 189.6 μM and 270.3 μM, respectively[1]. Following pretreatment with autophagy inhibitors, the accumulation of the microtubule-associated protein light chain 3B (LC3B)-II indicates that the chemical Sinomenine HCl (SH) activates an autophagy-mediated cell death pathway, initiates autophagic flux, and improves cell viability. By blocking the Akt-mTOR pathway and activating the JNK pathway, it causes autophagy. Sinomenine HCl (SH) increases the levels of autophagy marker proteins both in vivo and in vitro while dose-dependently decreasing the phosphorylation of p70S6K, 4E-BP1, Akt, and mTOR. Sinomenine HCl increases ROS production in a dose-dependent manner, which is accompanied by an increase in autophagy in both U87 and SF767 cells. By causing the nuclear translocation of TFEB through mTOR inhibition, SH may encourage lysosomal biogenesis[2].
|
|
| ln Vivo |
Sinomenine has anti-inflammatory, cardioprotective, and cancer-chemopreventive properties. In vivo, it demonstrates anti-glioma activity. At therapeutic doses, sinomenine is well tolerated by recipient mice and causes no discernible cytotoxicity[1]. Both in vitro and in vivo experiments show that the autophagy-lysosome pathway is started by the compound Sinomenine HCl (SH)[2].
|
|
| Cell Assay |
The cells are cultured in 96-well plates at a density of 5 × 103/well and subjected to SM treatment for the predetermined period of time (24–72 hours). The microplate is then incubated at 37 °C for 4 hours after adding 10 μl of MTT solution (5 g/l) to the medium in each well. A microplate reader reads the absorbance at 570 nm. The proportion of surviving cells compared to untreated cells is how cytotoxicity is measured.
|
|
| Animal Protocol |
Nude mice (male, 5-week-old BALB/c)
50 mg/kg and 100 mg/kg i.p. |
|
| References |
| Molecular Formula |
C19H24CLNO4
|
|---|---|
| Molecular Weight |
365.8512
|
| Exact Mass |
365.139
|
| Elemental Analysis |
C, 62.38; H, 6.61; Cl, 9.69; N, 3.83; O, 17.49
|
| CAS # |
6080-33-7
|
| Related CAS # |
Sinomenine;115-53-7
|
| PubChem CID |
5464452
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
513.6ºC at 760 mmHg
|
| Melting Point |
231.0 to 235.0 °C
|
| Flash Point |
264.4ºC
|
| LogP |
2.758
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
25
|
| Complexity |
562
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
Cl[H].O(C([H])([H])[H])C1C(C([H])([H])[C@@]23C4C(=C(C([H])=C([H])C=4C([H])([H])[C@@]([H])([C@@]2([H])C=1[H])N(C([H])([H])[H])C([H])([H])C3([H])[H])OC([H])([H])[H])O[H])=O
|
| InChi Key |
YMEVIMJAUHZFMW-VUIDNZEBSA-N
|
| InChi Code |
InChI=1S/C19H23NO4.ClH/c1-20-7-6-19-10-14(21)16(24-3)9-12(19)13(20)8-11-4-5-15(23-2)18(22)17(11)19;/h4-5,9,12-13,22H,6-8,10H2,1-3H3;1H/t12-,13+,19-;/m1./s1
|
| Chemical Name |
(1R,9S,10S)-3-hydroxy-4,12-dimethoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5,11-tetraen-13-one;hydrochloride
|
| Synonyms |
Sinomenine hydrochloride; Cucoline HCl; NSC76021; NSC 76021; NSC-76021
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~273.3 mM)
H2O: ~16.67 mg/mL (~45.6 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.69 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 25 mg/mL (68.33 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7334 mL | 13.6668 mL | 27.3336 mL | |
| 5 mM | 0.5467 mL | 2.7334 mL | 5.4667 mL | |
| 10 mM | 0.2733 mL | 1.3667 mL | 2.7334 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05764304 | Not yet recruiting | Drug: Sinomenine Drug: Glucocorticoid |
Knee Osteoarthritis | Shanghai 6th People's Hospital | February 28, 2023 | Phase 3 |
| NCT00409071 | Completed | Drug: Cocculine® Drug: placebo |
Breast Cancer | Centre Leon Berard | September 2005 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
